Predict your next investment

Corporation
HEALTHCARE
abbott.com

See what CB Insights has to offer

Investments

15

Portfolio Exits

7

Partners & Customers

10

Service Providers

2

About Abbott

Abbott (NYSE: ABT) is a global healthcare company with a portfolio of science-based offerings in diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals.

Abbott Headquarter Location

100 Abbott Park Road

Abbott Park, Illinois, 60064,

United States

+1 224 667 6100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Abbott

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Abbott in 6 Expert Collections, including Pharma Startups.

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

B

Bioelectronics

1,099 items

Companies developing/using technology aimed at detecting, interpreting, interrupting, eliciting, or redirecting electrical signals within the body

C

Conference Exhibitors

5,302 items

I

Infectious Disease

2,225 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

D

Diabetes

1,750 items

Abbott Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Abbott Rank

Research containing Abbott

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Abbott in 6 CB Insights research briefs, most recently on Jun 1, 2020.

Latest Abbott News

Abbott to debut bevvy of new innovations at CIIE

Oct 25, 2021

Date: 22 Oct 2021 Chicago-based healthcare company Abbott announced on Oct 19 that it will exhibit dozens of innovative healthcare solutions, including more than 10 that will be making their China debut, at the 4th China International Import Expo (CIIE) held in Shanghai from Nov 5 to 10. Major exhibits will include the world's first Bluetooth-enabled implantable cardioverter defibrillator that is compatible with the 3T MRI environment, the company said during its Tech Day 2021, a warm-up event that offered a preview of CIIE exhibits, in Shanghai. According to the company, the implantable cardioverter defibrillator will allow patients, physicians and caretakers to be connected through a mobile app and access data from implanted products at any time. The device also allows continuous monitoring that enhances patient safety and helps reduce the need for follow-up visits to the doctor. After exhibiting a fingerstick-free glucose monitoring system called Freestyle Libre at last year's CIIE, Abbott will display a relevant smart app, the latest digital tool of the FreeStyle Libre series, at the upcoming CIIE. The app can not only help diabetes patients monitor their real-time glucose levels but also share the data with their families and medical professionals through cloud technology. The app enables multiple caretakers to manage a patient simultaneously, and allows caregivers to monitor multiple patients at the same time, said the company. An innovative lab automation system, which was unveiled in February in China, will also be highlighted during the CIIE. The system, which is capable of multi-floor transportation, breaks barriers between departments and floors and allows medical workers to obtain testing results faster, thus significantly improving the efficiency of lab testing. "Thanks to the spill-over effect of the CIIE, the GLP system, which was showcased at the CIIE last year, attracted attention from different sides and many hospitals showed interest," said Tony Chan, vice-president of Abbott's core diagnostics business. "Some medical institutions, including several in Shanghai and Jinan, Shandong province, have already been equipped with the system to provide personalized total lab solutions." Source: China Daily Disclaimer The information on this page may have been provided by a contributor to ChinaGoAbroad, and ChinaGoAbroad makes no guarantees about the accuracy of any content. All content shall be used for informational purposes only. Contributors must obtain all necessary licenses and/or ownership rights from the relevant content owner(s) before submitting such content (including texts, pictures, photos and diagrams) to ChinaGoAbroad for publication. ChinaGoAbroad disclaims all liability arising from the publication of any content/information (such as texts, pictures, photos and diagrams that infringe on any copyright) received from contributors. Links may direct to third party sites out of the control of ChinaGoAbroad, and such links shall not be considered an endorsement by ChinaGoAbroad of any information contained on such third party sites. Please refer to our Disclaimer for more details.

Abbott Investments

15 Investments

Abbott has made 15 investments. Their latest investment was in Bigfoot Biomedical as part of their Series B - II on March 3, 2018.

CBI Logo

Abbott Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/28/2018

Series B - II

Bigfoot Biomedical

$18M

Yes

Undisclosed Investors

3

7/30/2015

Corporate Minority

Cephea Valve Technologies

Yes

1

9/30/2014

Series B

VytronUS

$31.6M

Yes

2

11/14/2007

Series D

Subscribe to see more

$99M

Subscribe to see more

10

1/19/2007

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/28/2018

7/30/2015

9/30/2014

11/14/2007

1/19/2007

Round

Series B - II

Corporate Minority

Series B

Series D

Series B

Company

Bigfoot Biomedical

Cephea Valve Technologies

VytronUS

Subscribe to see more

Subscribe to see more

Amount

$18M

$31.6M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Undisclosed Investors

Sources

3

1

2

10

10

Abbott Portfolio Exits

7 Portfolio Exits

Abbott has 7 portfolio exits. Their latest portfolio exit was Hydra Biosciences on December 14, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/14/2018

Asset Sale

2

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

12/14/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

Asset Sale

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Abbott Acquisitions

26 Acquisitions

Abbott acquired 26 companies. Their latest acquisition was Walk Vascular on September 02, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/2/2021

Acquired

2

1/16/2019

Corporate Minority

$14.71M

Acquired

1

10/3/2017

PIPE

$991

Acq - P2P

2

1/5/2017

IPO

Subscribe to see more

$991

$99M

Subscribe to see more

10

2/2/2016

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/2/2021

1/16/2019

10/3/2017

1/5/2017

2/2/2016

Investment Stage

Corporate Minority

PIPE

IPO

Private Equity

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Total Funding

$14.71M

$99M

$99M

Note

Acquired

Acquired

Acq - P2P

Subscribe to see more

Subscribe to see more

Sources

2

1

2

10

10

Abbott Partners & Customers

10 Partners and customers

Abbott has 10 strategic partners and customers. Abbott recently partnered with BioGaia on September 9, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

9/6/2021

Partner

BioGaia

Sweden

BioGaia, Abbott in partnership to distribute probiotics to medical professionals in Singapore

BioGaia has partnered with Abbott to distribute two of its probiotic products to medical professionals in Singapore .

2

8/18/2021

Licensor

Cereno Scientific

Sweden

Cereno Scientific collaborates with Abbott

Cereno Scientific has announced that a collaboration agreement has been entered with Abbott regarding use of its CardioMEMS HF System in the upcoming Phase II study with Cereno 's drug candidate CS1 .

1

7/16/2021

Licensee

Curative

United States

FDA grants Curative request to revoke COVID-19 test EUA, company pivots to Abbott kits after false result risk

The FDA notice comes one month after Curative disclosed a partnership with Abbott .

1

6/15/2021

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

6/8/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

9/6/2021

8/18/2021

7/16/2021

6/15/2021

6/8/2021

Type

Partner

Licensor

Licensee

Licensee

Partner

Business Partner

BioGaia

Cereno Scientific

Curative

Country

Sweden

Sweden

United States

Subscribe to see more

Subscribe to see more

News Snippet

BioGaia, Abbott in partnership to distribute probiotics to medical professionals in Singapore

BioGaia has partnered with Abbott to distribute two of its probiotic products to medical professionals in Singapore .

Cereno Scientific collaborates with Abbott

Cereno Scientific has announced that a collaboration agreement has been entered with Abbott regarding use of its CardioMEMS HF System in the upcoming Phase II study with Cereno 's drug candidate CS1 .

FDA grants Curative request to revoke COVID-19 test EUA, company pivots to Abbott kits after false result risk

The FDA notice comes one month after Curative disclosed a partnership with Abbott .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

Abbott Service Providers

2 Service Providers

Abbott has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Acq - P2P

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Partnership data by VentureSource

Abbott Team

35 Team Members

Abbott has 35 team members, including current President, Keith Boettiger.

Name

Work History

Title

Status

Keith Boettiger

President

Current

Jeffrey R Binder

President

Former

Eric S Fain

President, Senior Vice President

Former

Azita Gerhardt

President

Former

Chip Hance

President

Former

Name

Keith Boettiger

Jeffrey R Binder

Eric S Fain

Azita Gerhardt

Chip Hance

Work History

Title

President

President

President, Senior Vice President

President

President

Status

Current

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.